Plain-English translation of NCT06353126 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 4 โ The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) โ a procedure that delivers chemotherapy directly to liver cancer tumors through blood vessels โ can help prevent cancer from returning after a liver transplant. Patients scheduled for living donor liver transplantation will receive this medication two weeks before their surgery. The goal is to see if this extra step improves long-term survival and keeps the cancer from coming back.
Liver cancer often returns even after transplant, which can shorten survival. Researchers want to know if treating tumors with this targeted chemotherapy procedure just before transplant can reduce the risk of recurrence and help patients live longer.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you enroll, you will receive the DEB-TACE procedure (chemotherapy delivered directly to your tumor through blood vessels) about two weeks before your scheduled liver transplant surgery. The study will then follow you after transplant to monitor whether your cancer returns and how well you recover. Researchers will track your survival, how your body responds, and any side effects from the procedure.
AI-generated summary from trial data ยท Jul 12, 2026 ยท Not medical advice
China